Sentir

SmartGuard technology; Predictive Low Glucose technology

Medtronic Minimed, Inc. · K253585

FDA-authorized Predetermined Change Control Plan

1 of 15 AI hardware1 of 10 in Clinical Chemistryauthorized 2026
Company
Medtronic Minimed, Inc.
510(k)/De Novo #
K253585
Decision date
2026-01-14
Panel
Clinical Chemistry
Pathway
510(k)
Category
AI hardware
PCCP type
I/O expansion
Monitoring commitment
Not stated

What this PCCP covers. Permits input/output expansion to compatible devices

Browse

Other PCCPs from Medtronic Minimed, Inc.

Other Clinical Chemistry PCCPs

Want the monitoring teardown?

We read the PCCP for SmartGuard technology; Predictive Low Glucose technology, then map the post-market monitoring that its modification protocol requires, including the deployment-period evidence most teams can't reconstruct at modification time. Sentir is the independent system of record that produces it.

Book a call

Source: U.S. FDA public records (openFDA 510(k)/De Novo databases and accessdata.fda.gov). PCCP type and category are editorial classifications based on public documents, not official FDA designations.

This page is a factual summary of public FDA records. Sentir Health is not affiliated with or endorsed by the named companies or the U.S. Food and Drug Administration. Spot an error? Request a correction.